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Alpha-defensins 1-3 release by dendritic cells is
reduced by estrogen
Maria M Escribese1,2,3*†, Marta Rodríguez-García 4,5†, Rhoda Sperling6, Stephanie M Engel7, Teresa Gallart4 and
Thomas M Moran1,2
Abstract
Background: During pregnancy the immune system of the mother must protect any activation that may
negatively affect the fetus. Changes in susceptibility to infection as well as resolution of some autoimmune
disorders represent empirical evidence for pregnancy related alterations in immunity. Sex hormones reach
extremely high levels during pregnancy and have been shown to have direct effects on many immune functions
including the antiviral response of dendritic cells. Among the immunologically active proteins secreted by
monocyte derived DCs (MDDC) are the alpha-defensins 1-3. This family of cationic antimicrobial peptides has a
broad spectrum of microbicidal activity and has also been shown to link innate to adaptive immunity by attracting
T cells and immature DCs, which are essential for initiating and polarizing the immune response.
Methods: We compare culture-generated monocyte derived DCs (MDDCs) with directly isolated myeloid dendritic
cells (mDCs) and plasmacytoid dendritic cells (pDCs) and measure their alpha-defensins 1-3 secretion by ELISA
both, in basal situations and after hormone (E2 or PG) treatments. Moreover, using a cohort of pregnant women
we isolated mDCs from blood and also measure the levels of these anti-microbial peptides along pregnancy.
Results: We show that mDCs and pDCs constitutively produce alpha-defensins 1-3 and at much higher levels than
MDDCs. Alpha-defensins 1-3 production from mDCs and MDDCs but not pDCs is inhibited by E2. PG does not
affect alpha-defensins 1-3 in any of the populations. Moreover, alpha-defensins 1-3 production by mDCs was
reduced in the later stages of pregnancy in 40% of the patients.
Conclusions: Here, we demonstrate that mDCs and pDCs secrete alpha-defensins 1-3 and present a novel effect of
E2 on the secretion of alpha-defensins 1-3 by dendritic cells.
Background
Defensins are a family of cationic antimicrobial peptides
[1] that demonstrate a broad-spectrum of microbicidal
activity against bacteria, fungi and viruses [2]. Moreover,
recent evidence suggest that defensins also interact with
host immune cells playing an important role in both the
innate and adaptive immune response [3]. Two groups
of human defensins have been described based on their
structural characteristics: a- and b-defensins [1]. Both
types have antimicrobial activity against bacteria and
fungi as well as against enveloped virus such as influ-
enza, herpes virus, cytomegalovirus and HIV [2].
a-defensins 1-3 specifically, are secreted by monocytes,
monocyte-derived DCs [4], NK cells and gδT cells in
addition to neutrophils [2]. Moreover, a-defensins 1-3
have been detected throughout the female reproductive
tract (FRT) in non-pregnant women [5,6] as well as in
the amnion, chorion, placenta, amniotic fluids and cervi-
cal mucus plug from pregnant women [7-9]. Changes in
these peptides have also been reported to be involved in
several pregnancy complications such as preterm deliv-
ery and preeclampsia [7,10].
Dendritic cells (DCs), as immunological sentinels, are
crucial intermediates linking innate immunity to adap-
tive immunity. Upon exposure to microbial invaders,
they undergo a maturational change characterized by
the up-regulation of surface molecules involved in the
interaction with T cells and the release of numerous
cytokines. This culminates in their migration to lymph
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nodes, where microbe-derived peptides are presented to
specific T cells and initiation of the adaptive immune
response occurs [11,12]. Most studies utilize DCs gener-
ated from CD14+ monocyte precursors, monocyte
derived dendritic cells (MDDCs) cultured in cytokine-
supplemented media. However, fully functional DCs can
be directly isolated from human blood based upon the
surface expression of CD1c+ (mDCs) without the need
for cytokine differentiation. Other DC populations such
as the plasmacytoid DCs (pDCs) have been proposed as
important mediators of innate immunity because of
their ability to produce large amounts of type I inter-
feron (IFN) following viral infection.
Steroid sex hormones exert a powerful effect on var-
ious immune system functions [13,14]. The monthly
hormonal changes associated with the female menstrual
cycle also correlate with deviations in immunity [15].
However, the most drastic changes in immunity occur
during pregnancy when the levels of estrogen (E2) and
progesterone (PG) rise to extremely high concentrations
in the third trimester [16,17]. Some defensins, such as
HD-5 and HBD1-4 undergo variations at mucosal sur-
faces during the menstrual cycle [6,18], suggesting that
a-defensins 1-3 may be regulated by changes in hormo-
nal levels [19].
Numerous interactions between the endocrine and the
immune systems have been described [20-22]. Several
groups have shown that estrogen administration leads to
clinical improvement in experimental autoimmune ence-
phalomyelitis due to changes in DCs function and the
promotion of a Th2 immune response [23]. In contrast,
disease exacerbation has been reported to occur during
pregnancy in systemic lupus erythematosus (SLE)
patients [24]. Progesterone (PG) also causes a shift to a
Th2 dominated response by blocking the Th1 pathway,
inducing IL-10 and blocking IL12 [13,14].
E2 has a wide range of physiological activities, and it is
thought to act through two receptors ERa and ERb by
direct and indirect binding to promoter and/or enhancer
regions within target genes [25]. Receptors for PG and
E2 have been detected on some leukocytes [26,27] and
in particular on DCs [28]. At least three distinct classes
of anti-estrogens have been described. In this study we
have used a type I antagonists represented by ICI
182,780 that inhibits estrogen activity both in vivo and
in vitro. In contrast, type II and III, represented by
Tamoxifen and Raloxifene mimic the biological effects
of E2 in some specific tissues but oppose E2 action in
other [29].
In this report we demonstrate that directly isolated
DCs secrete a-defensins 1-3, and that E2 acts to inhibit
this secretion. This same trend is observed in mDCs iso-
lated from pregnant women in their first trimester (low
E2) and third trimester (high E2). Together these data
suggest a direct effect of E2 over the secretion of a-
defensins 1-3 by dendritic cells.
Methods
Isolation and culture of human DCs
PBMCs were isolated as previously described [30].
Briefly, Ficoll density gradient centrifugation (Histopa-
que; Sigma Aldrich) was performed using buffy coats
from healthy human donors (Mount Sinai Blood Donor
Center and New York Blood Center). CD14+ cells were
immunomagnetically purified using anti-human CD14+
antibody-labeled magnetic beads and iron-based Midi-
macs LS columns (Miltenyi Biotec). After elution from
the columns, these cells were plated (0.7 × 106 cells/ml)
in DC medium (RPMI [Invitrogen], 1% Human Serum,
100 units/ml of penicillin, and 100 μg/ml streptomycin
[Invitrogen]) supplemented with 500 U/ml human gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF;
Peprotech) and 1,000 U/ml human interleukin-4 (IL-4;
Peprotech) and incubated for 5 to 6 days at 37°C. mDC
and pDCs were immunologicaly purified using anti-
human CD1c (BDCA-1) and CD303 (BDCA-4) anti-
body-labeled magnetic beads (Miltenyi Biotec) and iron
based MiniMacs LS columns. After elution from col-
umns, cells were plated (1 × 106 cells/ml) and treated or
not with E2 or PG.
Hormone treatment and viral infection
After 5 to 6 days in culture at a 1 × 106 cell/ml concen-
tration, MDDCs were treated either with 17b-estradiol
(E2; Sigma) or with progesterone (PG; Sigma) at concen-
trations of 10 μg/ml, 1 μg/ml, 0.1 μg/ml and mock (0 ug/
ml). In some cases the MDDCs treated for 24 h with 10
ug/ml of E2 or PG were infected with New Castle Disease
Virus NDV-B1 for 10 h at and MOI (multiplicity of infec-
tion) of 0.5. mDCs and pDCs were treated with each spe-
cific condition right after their isolation. After mock or
E2/PG treatment supernatants were collected and a-
defensins 1-3 secretion was measured by ELISA.
ICI 182,780 treatment
MDDCs at day 2 in the differentiation process in a con-
centration of 1 × 106 cell/ml are treated with 10, 100
and 1000 nM of either ICI 182,780 (AstraZeneca) or the
vehicle (DMSO) for 3 days until day 5 of the differentia-
tion process. mDCs were pretreated with ICI 182,780
for 24 h previous to the hormonal treatment. Cell viabi-
lity, in both cell populations, was measured before and
after treatment by Trypan Blue (Invitrogen) exclusion.
After ICI 182,780 pre-treatment DCs were either mock
or E2 treated for 24 h and supernatants and cell lysates
were collected for further analysis.
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ELISAs
Capture enzyme-linked immunosorbent assays (ELISAs)
for HNP1-3 (Hycult Biotechnology) was used according
to the manufacturers’ instructions to quantify the a-
defensins 1-3 in the DC supernatants from pregnant
women. Plates were read in an ELISA reader from Bio-
tek Instruments assay following the manufacturer’s pro-
tocol and data were analyzed using software from
Applied Cytometry Systems. Levels of serum estradiol
and progesterone were measured by Lenetix Medical
Screening Laboratory, Inc., Mineola, New York.
Flow Cytometry
Cells were stained with CD14 FITC/CD11cPE (from BD
Bioscience), to verify the differentiation process from
monocytes to MDDCs. The staining was performed
according to the manufacturer’s instructions (Beckman
Coulter or BD-Pharmingen). The expression level of
each marker was determined by flow cytometry after
gating on the lineage-specific marker, using a FC 500
flow cytometer from Beckman Coulter. Data were ana-
lyzed using CXP software (Beckman Coulter).
RNA extraction and Quantitative real-time PCR from
human DCs
RNA extraction and RT-PCR was performed as
described before [30]. Briefly, samples of 1 × 106 DCs
differentially treated according to the experimental pro-
tocol were pelleted, and RNA was isolated and treated
with DNase using Absolutely RNA RT-PCR miniprep
kit (Stratagene, La Jolla, CA, USA). RNA was quantified
using a Nanodrop spectrophotometer (Nanodrop Tech-
nologies). The yields of RNA were approximately 20-50
ug/sample. qRT-PCR was performed by using a pre-
viously published SYBR green protocol with an ABI7900
HT thermal cycler [30]. Each transcript in each sample
was assayed two times, and the mean cycle threshold
was used to calculate the fold change for each gene.
Four housekeeping genes were used for global normali-
zation in each experiment (actin, Rps11, glyceraldehyde-
3-phosphate dehydrogenase, and tubulin genes) [31].
Data validity by modeling of reaction efficiencies and
analysis of measurement precision was determined as
described previously [30].
Patient samples
Maternal blood and serum samples utilized in these
experiments were obtained from the Viral Immunity in
Pregnancy (VIP) study, an ongoing NIH-funded project
which enrolls pregnant women during the first 20 weeks
of gestation and follows them through 6 months post
delivery in order to assess the interplay between mater-
nal systemic immunologic responses and enhanced sus-
ceptibility to viral pathogens. The study is IRB approved
by the Program for the Protection of Human Subjects at
the Mount Sinai School of Medicine. Peripheral blood
samples are collected from women at five specific time
points: study entry (< 20 weeks’ gestation), 25-27 weeks’
gestation, 34-36 weeks’ gestation, 6 weeks post-delivery
and 6 months post-delivery. Each woman’s perinatal or
6 weeks postpartum blood draw can be compared
against her own 6 month post-partum “normal” blood
draw, thus allowing each woman to serve as her own
control, implicitly accounting for interindividual varia-
tion in a number of factors. Women are recruited from
the general obstetrics practice at the Mount Sinai Hos-
pital in NYC. Exclusion criteria include: (1) Individuals
with known or suspected HIV infection; (2) Individuals
with a history of splenectomy, known auto-immune dis-
orders (systemic lupus erythematosus or rheumatoid
arthritis), or require chronic systemic immunosuppres-
sive therapy; (3) Individuals with a history of previous
bone marrow or organ transplant; (4) Individuals who
have received any immune globulin (including Rhogam)
or blood derived products within 3 months of study
enrollment; (5) Individuals who became pregnant using
a donor egg for this pregnancy; (6) Individuals with a
history of malignancy; and, (7) Individuals that will be
managed in the third trimester of pregnancy with epo-
gen. Individuals with asthma were eligible to participate
as long as they did not receive chronic oral steroid treat-
ment. Individuals with anemia, defined by a Hemoglobin
< 10 g/dl were excluded by the local IRB because of
safety concerns re: volume of blood donation required
by the study.
Statistical Analysis
Data were transformed with natural-logarithms. Mixed
models were used to examine changes in defensins dur-
ing pregnancy accounting for repeated measures taken
from the same women over time. The analyses were
performed using PROC MIXED of SAS, Version 9.2
(SAS Inc., Cary, NC). All P values were two-tailed, with
P < 0.05 considered as statistically significant. Statistical
analysis for changes in a-defensins 1-3 induce by hor-
mones treatments was performed by analysis of
variance, and a P value less than .05 was considered
significant.
Results
Myeloid DCs (mDCs) and plasmacytoid (pDCs) secrete
a-defensins 1-3
We have previously reported that a-defensins 1-3 levels
were almost undetectable in monocytes but when differ-
entiated into DCs (MDDCs) after 7 days in culture, they
produce and secrete a-defensins 1-3 [4]. In order to
determine if these cultured cells were representative of
DC populations circulating in vivo, mDCs (CD1c+) and
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pDCs (BCDA-4+) were directly isolated from buffy coats
as well as MMDCs. After 6 h in culture the levels of a-
defensins 1-3 secreted into the supernatants were mea-
sured. As a control we used monocytes (negative con-
trol) and PBMC (positive control), that has been
described to secrete a-defensins 1-3 constitutively [32]
(Figure 1A, right panel). A comparison of the constitu-
tive secretion of a-defensins 1-3 from MDDCs, mDCs
and pDCs by ELISA show that the levels of a-defensins
1-3 detected in the supernatants from mDCs and pDCs
B)
A)
100
1000
10000
MDDCs mDCs pDCs
a-
de
ef
ns
in
s
1-
3 
(p
g/
m
l) *p<0.01
C)
Estrogen
*p<0.05
0
50
100
150
200
250
300
Mock 10ug/ml 1ug/ml 0.1 ug/ml
a-
de
fe
ns
in
s 
1-
3 
(p
g/
m
l)
Progesterone
0
40
80
120
160
Mock 10ug/ml 1ug/ml 0,1ug/ml
a-
de
fe
ns
in
s 
1-
3 
(p
g/
m
l)
**p<0.001
1
1000
1000000
PBMC Monocytes
a-
de
fe
ns
in
s 
1-
3 
(p
g/
m
l)
*p<0.05
0
50
100
150
200
Mock Mock 10ug/ml E2 10ug/ml PG
Mock NDVB1 NDVB1 NDVB1 
a-
de
fe
ns
in
s 
1-
3 
(p
g/
m
l)
Figure 1 MDDCs secrete a-defensins 1-3: E2 and PG effect. A) ELISA quantification of a-defensins 1-3 secreted by MDDCs, mDCs and pDCs
(left panel) or PBMCs and monocytes (right panel) in the supernatant after 6 h of culture. Data are presented as mean plus or minus SD from 3
independent experiments.*P < 0.01 and *P < 0.001 versus MDDCs levels. Data are presented in a log scale. Levels of a-defensins 1-3 measured
by ELISA in: (B) MDDCs treated for 24 h with 10, 1 and 0.1 ug/ml of E2 (left panel) or PG (right panel). (C) MDDCs pretreated for 24 h with E2 or
PG (10 ug/ml) before NDV-B1 infection for 10 h. Data are presented as mean plus or minus SD from 3 independent experiments. *P < 0.05versus
MDDCs levels.
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were 10 and 15-fold higher, respectively, than those
detected in the supernatants from MDDCs (Figure 1A,
left panel) (p < 0.01).
Estrogen but not Progesterone down-regulates a-
defensins 1-3 secretion by DCs
Estrogen exerts an inhibitory effect on mDC and MDDC
secretion of type I interferon (IFN) and some inflamma-
tory cytokines [28]. Therefore we measured the effect of
estrogen (E2) and progesterone (PG) on a-defensins 1-3
secretion by MDDCs, mDCs and pDCs. Treatment of
MDDCs with E2 resulted in a dose-dependent reduction
in a-defensin 1-3 secretion. Conversely, PG treatment
had no effect on the secretion of a-defensins 1-3 in
MDDCs (Figure 1B). Moreover, we also show that E2
but not PG still have a significant (*p < 0.05 vs mock
treated DCs) inhibitory effect in the secretion of a-
defensins 1-3 in viral infected MDDCs (Figure 1C), that
correlates with our previous report describing the
immunosuppressive effect of E2 during viral infection
[28].
We also analyzed the effect of E2-treatment on the
secretion of a-defensins 1-3 by mDCs and in accor-
dance with the results observed for MDDCs, a signifi-
cant reduction in the levels of a-defensins 1-3 was
detected in cells treated with high concentrations of E2
but PG treatment did not have any significant effect
(Figure 2A). In contrast, the a-defensins 1-3 secretion
by pDCs was not affected by estrogen (Figure 2B).
These results show that E2 suppresses a-defensins 1-3
secretion by mDCs and MDDCs but not in pDCs.
Effect of ICI 182,780 in the secretion of a-defensins 1-3
by DCs
In order to determine if the reduction of a-defensins 1-
3 secretion was specific and mediated through the estro-
gen receptor, DCs were treated with the estrogen recep-
tor (ER) antagonist ICI 182,780 at a concentration of
1000 nM, 100 nM and 10 nM for 3 days prior to the E2
treatment. Since E2 upregulates ER expression, ERa
transcription in the presence of E2 is a useful measure
of the effectiveness of ICI 182,780. At the highest con-
centration of ICI 182,780 in the presence of 10 ug/ml
E2 a significant reduction of 2.5 -folds in ERa expres-
sion was observed (Figure 3A). This concentration of
the drug was able to reverse the inhibition of E2 on a-
defensins 1-3 secretion by both types of DCs (Figure
3B). However, low concentrations for Faslodex (100 and
10 nM) do not significantly change (1.24 and 0.92-
folds, respectively) ERa expression in relation with the
levels detected in untreated MDDCs. Moreover, 1000
nM ICI 182,780 did not affect the differentiation process
of the MDDCs measured by CD11c and CD14 expres-
sion at day 5 of culture (Figure 3C). These results
confirmed that the effect of E2 on a-defensins 1-3
secretions was mediated through estrogen receptor sig-
naling and that a novel E2 regulated mechanism pre-
vents a-defensins 1-3 secretion in DCs.
Secretion of a-defensins 1-3 by DCs during pregnancy
Since estrogen levels rise significantly in women from the
first to the third trimester of pregnancy we speculated
that if estrogen was exerting regulatory control over a-
defensins 1-3 secretion, then the mDCs collected late in
pregnancy should produce less of these anti-microbial
peptides. A cohort of women from an ongoing study of
immunity during pregnancy being performed at Mount
Sinai School of Medicine (VIP study) were chosen based
upon their significant difference in serum estrogen levels
between the first and third trimester (Figure 4A). mDCs
were isolated from these subjects and the secretion of a-
defensins 1-3 was measured by capture ELISA after 12 h
in culture. However, patient variation was great and no
statistical difference between the groups could be demon-
strated. a-defensins 1-3 release by DCs isolated from 40%
of the patients showed at least a two-fold reduction
between the 1st and 3rd trimester as estrogen levels rose.
However, many (50%) showed no significant change and
two patients showed a more than a two fold rise in secre-
tion (10%) (Figure 4B).
Discussion
During normal pregnancy, the maternal immune system
remains systemically immunocompetent [33,34]. How-
ever, it is faced with a dilemma that it must continue to
protect the mother against infection while inhibiting
immune activation against the semiallogeneic fetus.
There is clear evidence that in the later stages of preg-
nancy women are uniquely susceptible to microbial
infection. The prevailing view, though not shared by all,
is that the predominant immune response is shifted
from a gamma interferon based Th1 response to a less
inflammatory Th2 response. The period of enhanced
sensitivity to infection corresponds to the extremely
high concentrations of E2 and PG that are reached in
the later stages of pregnancy [16,17]. Both E2 and PG
have been shown to exert a powerful effect on various
aspects of the innate and adaptive immune response
[13,14]. In a previous publication we investigated the
effect of these hormones on the activation of DCs cul-
tured from monocytes as well as those isolated directly
from the blood. PG did not exert any effect on DCs in
either the steady state or after activation by viruses. In
contrast, E2 was a potent inhibitor of DC activation trig-
gered by a number of human viruses but not by toll-like
receptors ligands (TLRs) [28].
Alpha-defensins 1-3 are small peptides that can act
both as natural antibiotics by directly killing a wide
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range of microorganisms and by participating in adap-
tive immunity by attracting monocytes, T cells, or
immature DCs [35,36]. Moreover, a-defensins 1-3 have
been detected throughout the female reproductive tract
(FRT) in non-pregnant women [5,6] as well as in the
amnion, chorion, placenta, amniotic fluids and cervical
mucus plug from pregnant women [7-9]. Previous
reports by us and others demonstrate the expression of
a-defensins 1-3 by immune cells populations including
MDDCs [4], NK cell, B cells, gδTcells, mast cells, neu-
trophils [2]. Most human DC studies are performed
using MDDCs produced by culturing these cells in the
presence of the cytokines GM-CSF and IL4. It is not
known whether cells produced this way simulate in vivo
DC populations. However, mDCs as well as pDCs can
be isolated directly from human blood by the expression
of the CD1c marker (mDC) or BCDA4 (pDC) on their
surface [37]. In this report we analyzed directly isolated
mDCs and pDCs and show that they both secrete signif-
icantly more a-defensins 1-3 than MDDCs. These
results suggest that culturing of DCs may reduce their
a-defensin 1-3 secretion and that previous work may
have underestimated the contribution of DCs to in vivo
a-defensin 1-3 production [38].
17-b-estradiol (E2), one of the most important forms
of estrogen, acts through binding to two known hor-
mone receptors, estrogen receptors ERa and ERb [25],
which are expressed in specific tissues as well as in
immune cells, including macrophages, CD8+ T cells,
CD4+ T cells, B cells, monocytes, and DCs [39]. Cells
pre-treated with ICI 182, 780, a specific ER antagonist,
became insensitive to the inhibitory effect of E2, demon-
strating a direct and specific effect of E2 on the release
of a-defensins 1-3 by DCs. However, intrinsic or subse-
quently acquired resistance to the therapy remains a
major obstacle in treatment with this compound as has
been describe by Zhao et al., using a cell line of breast
cancer [40]. These open new questions that should be
addressed in further investigations with dendritic cells.
In our system, ICI 182,780 reduces the expression of the
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Figure 2 mDCs and pDCs secrete a-defensins 1-3: E2 and PG effect. Levels of a-defensins 1-3 measured by ELISA in: (A) mDCs treated for
24 h with 10, 1 and 0.1 ug/ml of E2 (left panel) or PG (right panel). (B) pDCs treated with 10 ug/ml of E2 for 8 h. Data are presented as mean
plus or minus SD from 3 independent experiments.*P < 0.05 versus Mock treated DCs.
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ER, as a result of the induction of a proteasome-depen-
dent degradation induced by this compound [41]. How-
ever, ICI 182,780 treatment does not affect the
differentiation of monocytes into MDDCs as measured
by percentage of CD11c+CD14- cells.
E2 but not PG suppressed the a-defensins 1-3 pro-
duction from the mDCs at high concentration but had
no effect on pDC a-defensins 1-3 secretion. This result
is consistent with our earlier observation that E2 did
not inhibit activation or cytokine secretion from pDCs.
A possible explanation for these observations comes
from the work of Hartman et al who demonstrated
that murine pDCs derive exclusively from estrogen-
resistant myeloid progenitors [42] which may explain
the failure of E2 to alter a-defensin 1-3 production by
these cells.
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Figure 3 ICI 182,780 revert E2-inhibitory effect in the release of a-defensins 1-3 by DCs. CD14+ cells isolated from fresh blood were
cultured for 5 days in the presence of IL-4 and GM-CSF to differentiate into DCs. The cells were treated with 10, 100 and 1000 nM of ICI 182,780
for the last 3 days of the differentiation process. (A) Levels of ERa measured by RT-PCR in DCs treated or not with ICI 182,780 in the presence of
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Based upon our in vitro studies we expected that
mDCs collected from the blood in the later part of preg-
nancy would show a reduction in a-defensins 1-3 pro-
duction. Moreover, evidence suggests that elevated
levels of a-defensins 1-3 in serum correlated with
adverse pregnancy outcomes [43,44]. While we observed
a trend towards less a-defensins 1-3 production from
DCs collected in the 3rd trimester relative to those col-
lected from the same patient in the 1st trimester, the dif-
ference was not statistically significant. Almost 40% of
the patients did show a very substantial drop in a-
defensins 1-3 release from their mDCs at third
trimester, while the remaining patients secreted a-
defensins 1-3 at nearly identical levels to what was
observed in the 1st trimester. It is worth noting, how-
ever, that the levels of estrogen detected in serum were
lower than the dose that most effectively inhibited a-
defensin 1-3 secretion in vitro.
Among the 50% failed to show a reduction, the consis-
tency of the mDC a-defensin 1-3 secretion within
patients and variation between patients (ranging from
10 ng/ml to 60 ng/ml) was significant. This high inter-
donor variability has been well described and likely cor-
responds to variations in the copy number of the genes
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that encode for a-defensins 1-3 between individuals
[45].
The sum of the a-defensin 1-3 production by mDCs
suggested a net loss in the later stages of pregnancy. If
other cells that produce a-defensins 1-3 were likewise
affected, serum a-defensins1-3 during pregnancy would
be expected to drop.
In this report we document that myeloid and plasma-
cytoid DCs directly isolated from the blood produce
substantial amounts of a-defensins 1-3 constitutively.
pDCs are not affected, but both mDCs and MDDCs
produce less a-defensins 1-3 in the presence of high
levels of E2. Alpha-defensins 1-3 release from mDCs
collected in the third trimester of pregnancy either fell
or stayed the same in the majority of the patients.
Conclusions
Our results demonstrate a specific effect for E2 on the
secretion of a-defensins 1-3 by dendritic cells. Moreover,
we also observed this effect in dendritic cells isolated
from pregnant women at third trimester, when the
levels of E2 reach extremely high concentrations.
Together, this data provide new insights that contribute
to explain immune changes during pregnancy.
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